Statin use and the risk of Clostridium difficile in academic medical centres

Department of Epidemiology and Community Health, Virginia Commonwealth University, School of Medicine, 830 E. Main Street, RM 5010, P.O. Box 980212, Richmond, VA 23298-0212, USA
Gut (Impact Factor: 14.66). 03/2012; 61(11):1538-42. DOI: 10.1136/gutjnl-2011-301378
Source: PubMed


To estimate the possible relationship between statin use and the risk of healthcare facility onset Clostridium difficile.
Patients over 18 years of age admitted to hospitals contributing data to the University HealthSystem Consortium between 2002 and 2009 were eligible. Patients with the ICD-9-CM code 008.45 who received a minimum 3-day course of either metronidazole or oral vancomycin on/after day 5 of admission were considered incident cases of C difficile infection. 31 472 incident cases of C difficile infection were identified and matched to five controls, on hospital, year/quarter of admission date, and age ±10 years (N=78 096). Patients who were administered one drug in the statin class (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin or simvastatin) before the index date were considered to be exposed. Conditional logistic regression modelling provided adjusted odds ratios and 95% CI.
Compared with non-users, users of any drug within the statin class were 0.78 times less likely to develop C difficile infection in the hospital (95% CI 0.75 to 0.81) adjusting for potential confounders. Differences in estimates for specific statins were minimal. Niacin, fibrates and selective cholesterol absorption inhibitors showed no association with the risk of C difficile infection.
Our data were consistent with a growing body of literature demonstrating a reduced risk of infections with statin use. Statins' pleiotropic properties may provide protection against C difficile infection.

Download full-text


Available from: Giovanni Gambassi, Oct 07, 2015
13 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Statins are a class of lipid-lowering drugs which decrease cholesterol synthesis and have beneficial effects on cardiovascular disease. Observational studies have ascribed many other beneficial effects of statins, including reduced risk of infections, cancer and Alzheimer's.1 The authors argue that these myriad beneficial observations are plausible as ‘pleiotropic’ or multiple effects of statins including anti-inflammatory, antioxidant, immunomodulatory, antiapoptotic, antiproliferative, antithrombotic, antimicrobial and endothelium-protecting properties2 have been demonstrated in the laboratory. However, are these beneficial effects too good to be true? It has been suggested that many of the apparent observed beneficial effects of statins can be explained by a ‘healthy user effect’. Statin users, especially compliant users, have been shown to be more likely to be insured, live at home, to have stopped smoking and to be more likely to engage in other positive health behaviours such as undergoing cancer screening and being vaccinated.3 ,4 Studies using administrative databases often are unable to adjust for these variables, and three studies on patients with pneumonia4-6 which adjusted for some of these variables found no decreased risk of pneumonia associated with current use of statins, and even reported a tendency towards increased risk. Motzkus-Feagans and colleagues … [Full text of this article]
    Gut 05/2012; 61(11):1523-4. DOI:10.1136/gutjnl-2012-302421 · 14.66 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Statins are prescribed to lower plasma cholesterol concentrations and prevent associated cardiovascular complications. Beside their lipid-lowering effect, these agents exhibit pleiotropic effects, especially on the immune system. In intensive care patients with severe sepsis, there is a growing interest to know whether statins are beneficial. Several studies underline the association between the long-term use of statins and a lower incidence of sepsis, complications and sepsis-related mortality. Although evidences suggest maintaining the administration in intensive care in patients already taking statins, there are currently no data supporting a prescription de novo in septic ICU patients.
    Le Praticien en Anesthésie Réanimation 11/2012; 16(5):296–307. DOI:10.1016/j.pratan.2012.10.002
  • Source
    Alimentary Pharmacology & Therapeutics 01/2013; 37(2):285-6. DOI:10.1111/apt.12157 · 5.73 Impact Factor
Show more

Similar Publications